CLINICAL TRIALS PROFILE FOR ZIAGEN
✉ Email this page to a colleague
All Clinical Trials for Ziagen
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004585 ↗ | A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults | Completed | Glaxo Wellcome | Phase 4 | 1999-10-01 | The purpose of this study is to see if a certain combination of anti-HIV drugs is safe and effective in HIV-infected patients. The drug combination includes a tablet containing lamivudine and zidovudine (called Combivir) plus abacavir plus efavirenz. |
| NCT00004981 ↗ | Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir) | Unknown status | Glaxo Wellcome | Phase 3 | 1969-12-31 | The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir. |
| NCT00005017 ↗ | Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment | Unknown status | Glaxo Wellcome | Phase 4 | 1969-12-31 | The purpose of this study is to see how effective and safe it is to give 1 of the 3 following treatments to patients who may not have received anti-HIV treatment: 1) lamivudine (3TC)/abacavir (ABC)/stavudine (d4T); 2) 3TC/ABC/efavirenz (EFV); or 3) 3TC/ABC/amprenavir (APV)/ritonavir (RTV). |
| NCT00038506 ↗ | Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure | Completed | ViiV Healthcare | Phase 4 | 2002-03-01 | This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen. |
| NCT00085943 ↗ | KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks | Completed | GlaxoSmithKline | Phase 3 | 2004-05-01 | This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Ziagen
Condition Name
Clinical Trial Locations for Ziagen
Trials by Country
Clinical Trial Progress for Ziagen
Clinical Trial Phase
Clinical Trial Sponsors for Ziagen
Sponsor Name
